Literature DB >> 22068512

Larger companies dominate cancer companion diagnostic approvals.

Charles Schmidt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068512     DOI: 10.1038/nbt1111-955

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Pegloticase.

Authors:  Naomi Schlesinger; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

  1 in total
  4 in total

Review 1.  An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.

Authors:  N A Meadows; A Morrison; D A Brindley; A Schuh; R W Barker
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

2.  Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Authors:  Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen
Journal:  Clin Cancer Res       Date:  2013-02-19       Impact factor: 12.531

3.  A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.

Authors:  Tzu-Yi Yang; Christie L Eissler; Mark C Hall; Laurie L Parker
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

4.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.